Mario Stegert

1.4k total citations
15 papers, 1.2k citations indexed

About

Mario Stegert is a scholar working on Molecular Biology, Hematology and Cell Biology. According to data from OpenAlex, Mario Stegert has authored 15 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Hematology and 5 papers in Cell Biology. Recurrent topics in Mario Stegert's work include Acute Myeloid Leukemia Research (5 papers), Hippo pathway signaling and YAP/TAZ (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Mario Stegert is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Hippo pathway signaling and YAP/TAZ (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Mario Stegert collaborates with scholars based in Switzerland, United States and Germany. Mario Stegert's co-authors include Brian A. Hemmings, Alexander Hergovich, Rastislav Tamaskovic, Samuel J. Bichsel, Debora Schmitz, Christine Dierks, Katja Zirlik, Annette Schmitt‐Graeff, Paul W. Manley and Markus Warmuth and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Nature Reviews Molecular Cell Biology.

In The Last Decade

Mario Stegert

15 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mario Stegert Switzerland 10 848 534 198 197 120 15 1.2k
Kaori Shinmyozu Japan 18 952 1.1× 144 0.3× 105 0.5× 114 0.6× 52 0.4× 28 1.2k
Kelly Morgan United States 13 1.1k 1.2× 74 0.1× 281 1.4× 179 0.9× 172 1.4× 25 1.3k
Hideki Izumi Japan 17 883 1.0× 412 0.8× 38 0.2× 327 1.7× 40 0.3× 33 1.2k
Kiran Batta United Kingdom 16 853 1.0× 130 0.2× 74 0.4× 100 0.5× 35 0.3× 29 1.1k
Valeria Naim France 16 1.1k 1.4× 451 0.8× 42 0.2× 199 1.0× 20 0.2× 21 1.3k
Aruna Purohit United States 7 1.1k 1.3× 1.0k 1.9× 35 0.2× 332 1.7× 33 0.3× 8 1.4k
Mélanie Laurin Canada 11 594 0.7× 221 0.4× 36 0.2× 117 0.6× 47 0.4× 16 800
R Prasad United States 11 1.6k 1.8× 148 0.3× 901 4.6× 143 0.7× 138 1.1× 11 2.0k
Hong Luo United States 16 447 0.5× 119 0.2× 151 0.8× 299 1.5× 141 1.2× 35 999
Danielle Martinet Switzerland 18 767 0.9× 107 0.2× 69 0.3× 143 0.7× 144 1.2× 27 1.1k

Countries citing papers authored by Mario Stegert

Since Specialization
Citations

This map shows the geographic impact of Mario Stegert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Stegert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Stegert more than expected).

Fields of papers citing papers by Mario Stegert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Stegert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Stegert. The network helps show where Mario Stegert may publish in the future.

Co-authorship network of co-authors of Mario Stegert

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Stegert. A scholar is included among the top collaborators of Mario Stegert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Stegert. Mario Stegert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Zeidan, Amer M., Jörg Westermann, Tibor Kovacsovics, et al.. (2022). P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. HemaSphere. 6. 481–482. 10 indexed citations
2.
Zeidan, Amer M., Jörg Westermann, Tibor Kovacsovics, et al.. (2022). AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML). Clinical Lymphoma Myeloma & Leukemia. 22. S255–S255. 12 indexed citations
3.
Zeidan, Amer M., Jörg Westermann, Tibor Kovacsovics, et al.. (2022). Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML). Clinical Lymphoma Myeloma & Leukemia. 22. S125–S125. 1 indexed citations
4.
Schulte, Johannes H., Lucas Moreno, David S. Ziegler, et al.. (2020). Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).. Journal of Clinical Oncology. 38(15_suppl). 10505–10505. 9 indexed citations
5.
Zeidan, Amer M., Jordi Esteve, Aristoteles Giagounidis, et al.. (2020). The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML). Blood. 136(Supplement 1). 45–46. 23 indexed citations
6.
Zeidan, Amer M., Jordi Esteve, Hee‐Je Kim, et al.. (2020). AML-187: The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 20. S188–S188. 3 indexed citations
7.
8.
André, François, Salomon M. Stemmer, G. N. Hortobagyi, et al.. (2016). Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics. European Journal of Cancer. 69. S7–S7. 4 indexed citations
9.
Cornils, Hauke, Mario Stegert, Alexander Hergovich, et al.. (2010). Ablation of the Kinase NDR1 Predisposes Mice to the Development of T Cell Lymphoma. Science Signaling. 3(126). ra47–ra47. 55 indexed citations
10.
Dierks, Christine, Katja Zirlik, Mario Stegert, et al.. (2008). Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation. Cancer Cell. 14(3). 238–249. 407 indexed citations
11.
Hergovich, Alexander, Mario Stegert, Debora Schmitz, & Brian A. Hemmings. (2006). NDR kinases regulate essential cell processes from yeast to humans. Nature Reviews Molecular Cell Biology. 7(4). 253–264. 264 indexed citations
12.
Stegert, Mario, Alexander Hergovich, Rastislav Tamaskovic, Samuel J. Bichsel, & Brian A. Hemmings. (2005). Regulation of NDR Protein Kinase by Hydrophobic Motif Phosphorylation Mediated by the Mammalian Ste20-Like Kinase MST3. Molecular and Cellular Biology. 25(24). 11019–11029. 136 indexed citations
13.
Bichsel, Samuel J., Rastislav Tamaskovic, Mario Stegert, & Brian A. Hemmings. (2004). Mechanism of Activation of NDR (Nuclear Dbf2-related) Protein Kinase by the hMOB1 Protein. Journal of Biological Chemistry. 279(34). 35228–35235. 114 indexed citations
14.
Stegert, Mario, Rastislav Tamaskovic, Samuel J. Bichsel, Alexander Hergovich, & Brian A. Hemmings. (2004). Regulation of NDR2 Protein Kinase by Multi-site Phosphorylation and the S100B Calcium-binding Protein. Journal of Biological Chemistry. 279(22). 23806–23812. 67 indexed citations
15.
Tamaskovic, Rastislav, Samuel J. Bichsel, Hélène Rogniaux, Mario Stegert, & Brian A. Hemmings. (2003). Mechanism of Ca2+-mediated Regulation of NDR Protein Kinase through Autophosphorylation and Phosphorylation by an Upstream Kinase. Journal of Biological Chemistry. 278(9). 6710–6718. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaori Shinmyozu Breakdown of academic impact, for papers by Kelly Morgan Breakdown of academic impact, for papers by Hideki Izumi Breakdown of academic impact, for papers by Kiran Batta Breakdown of academic impact, for papers by Valeria Naim Breakdown of academic impact, for papers by Aruna Purohit Breakdown of academic impact, for papers by Mélanie Laurin Breakdown of academic impact, for papers by R Prasad Breakdown of academic impact, for papers by Hong Luo Breakdown of academic impact, for papers by Danielle Martinet
Rankless by CCL
2026